Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:DVAXNASDAQ:FOLDNASDAQ:IONS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$29.90$29.95$22.90▼$36.45$4.93B0.511.77 million shs2.58 million shsDVAXDynavax Technologies$9.50-2.9%$11.16$9.22▼$14.63$1.14B1.262.22 million shs2.31 million shsFOLDAmicus Therapeutics$6.10-2.2%$6.93$5.81▼$12.65$1.88B0.642.86 million shs5.50 million shsIONSIonis Pharmaceuticals$32.43-2.7%$30.58$23.95▼$52.34$5.16B0.151.56 million shs2.86 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%-2.06%+7.13%-12.16%+25.89%DVAXDynavax Technologies-2.86%-4.04%-15.71%-30.04%-17.39%FOLDAmicus Therapeutics-2.24%-3.79%-17.46%-33.62%-36.33%IONSIonis Pharmaceuticals-2.67%-3.19%+9.05%+3.44%-13.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.827 of 5 stars4.43.00.04.23.61.71.9DVAXDynavax Technologies4.4416 of 5 stars3.33.00.04.72.71.71.9FOLDAmicus Therapeutics4.0194 of 5 stars3.41.00.04.33.70.01.9IONSIonis Pharmaceuticals4.451 of 5 stars4.31.00.03.04.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.77Moderate Buy$38.8529.92% UpsideDVAXDynavax Technologies 2.50Moderate Buy$24.00152.63% UpsideFOLDAmicus Therapeutics 2.70Moderate Buy$16.22165.94% UpsideIONSIonis Pharmaceuticals 2.65Moderate Buy$56.6774.74% UpsideCurrent Analyst Ratings BreakdownLatest DVAX, IONS, ALKS, and FOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$45.005/20/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/7/2025DVAXDynavax TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $31.005/2/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/2/2025ALKSAlkermesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$39.00 ➝ $40.005/2/2025ALKSAlkermesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$38.00 ➝ $41.005/2/2025FOLDAmicus TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.005/2/2025FOLDAmicus TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.005/1/2025IONSIonis PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$65.00 ➝ $64.005/1/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $50.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.51B3.26$2.24 per share13.32$9.05 per share3.30DVAXDynavax Technologies$294.62M3.87N/AN/A$4.81 per share1.98FOLDAmicus Therapeutics$543.14M3.46N/AN/A$0.63 per share9.68IONSIonis Pharmaceuticals$717.25M7.20N/AN/A$3.70 per share8.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0913.7821.822.2023.57%30.80%19.09%7/23/2025 (Estimated)DVAXDynavax Technologies-$6.39M-$0.5252.7819.39N/A9.85%4.22%2.67%8/5/2025 (Estimated)FOLDAmicus Therapeutics-$151.58M-$0.09N/A14.191.51-10.62%12.44%2.60%8/14/2025 (Estimated)IONSIonis Pharmaceuticals-$366.29M-$2.99N/AN/AN/A-64.25%-100.05%-15.70%8/7/2025 (Estimated)Latest DVAX, IONS, ALKS, and FOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025DVAXDynavax Technologies$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 million5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 million4/30/2025Q1 2025IONSIonis Pharmaceuticals-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.042.65DVAXDynavax Technologies0.3313.2312.34FOLDAmicus Therapeutics2.013.392.42IONSIonis Pharmaceuticals2.128.478.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%DVAXDynavax Technologies96.96%FOLDAmicus TherapeuticsN/AIONSIonis Pharmaceuticals93.86%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%DVAXDynavax Technologies2.98%FOLDAmicus Therapeutics2.20%IONSIonis Pharmaceuticals2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,280164.90 million154.66 millionOptionableDVAXDynavax Technologies350120.08 million127.54 millionOptionableFOLDAmicus Therapeutics480307.93 million292.23 millionOptionableIONSIonis Pharmaceuticals800159.16 million153.62 millionOptionableDVAX, ALKS, IONS, and FOLD HeadlinesRecent News About These CompaniesVoloridge Investment Management LLC Sells 63,698 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)May 27 at 4:46 AM | marketbeat.comWoodline Partners LP Purchases New Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)May 27 at 4:45 AM | marketbeat.comD. E. Shaw & Co. Inc. Reduces Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)May 26 at 3:34 AM | marketbeat.comDecember 2027 Options Now Available For Ionis Pharmaceuticals (IONS)May 25, 2025 | nasdaq.comIonis’ olezarsen shows new promise with strong Phase III resultsMay 23, 2025 | thepharmaletter.comHC Wainwright Reiterates Buy Rating for Ionis Pharmaceuticals (NASDAQ:IONS)May 23, 2025 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Earns "Buy" Rating from HC WainwrightMay 22, 2025 | marketbeat.comTwo Sigma Advisers LP Boosts Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)May 22, 2025 | marketbeat.comMillennium Management LLC Raises Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)May 22, 2025 | marketbeat.comVestal Point Capital LP Acquires New Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)May 21, 2025 | marketbeat.comIonis Builds Triglyceride-Lowering Case for RNA-Targeting TryngolzaMay 20, 2025 | biospace.com6IONS : Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 14...May 20, 2025 | benzinga.comIonis' Tryngolza Cuts Triglyceride Levels in Late-Stage StudyMay 20, 2025 | zacks.comTanaka Capital Management Inc. Decreases Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)May 20, 2025 | marketbeat.comTema Etfs LLC Purchases New Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)May 20, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Bought by Rafferty Asset Management LLCMay 20, 2025 | marketbeat.comIonis chalks up phase 3 trial win as it works to grow the reach of TryngolzaMay 20, 2025 | fiercepharma.comIonis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglyceridesMay 20, 2025 | finance.yahoo.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Ensign Peak Advisors IncMay 18, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Holdings Boosted by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLCMay 15, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Holdings Raised by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBy Leo Miller | May 27, 2025View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsBy Ryan Hasson | May 5, 2025View Rocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsSMCI Stock Rally: 45% Gain in 2 Days Could Be Just the StartBy Thomas Hughes | May 14, 2025View SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the StartBuybacks and Big-Time Developments: 3 Stocks Making Huge MovesBy Leo Miller | May 19, 2025View Buybacks and Big-Time Developments: 3 Stocks Making Huge MovesDVAX, ALKS, IONS, and FOLD Company DescriptionsAlkermes NASDAQ:ALKS$29.90 0.00 (0.00%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$29.90 +0.01 (+0.02%) As of 05/28/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Dynavax Technologies NASDAQ:DVAX$9.50 -0.28 (-2.86%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$9.64 +0.15 (+1.53%) As of 05/28/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Amicus Therapeutics NASDAQ:FOLD$6.10 -0.14 (-2.24%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$6.10 0.00 (-0.08%) As of 05/28/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ionis Pharmaceuticals NASDAQ:IONS$32.43 -0.89 (-2.67%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$32.42 -0.01 (-0.02%) As of 05/28/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
